Clinical Trial Detail

NCT ID NCT02673333
Title Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

adrenal cortex cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.